Promoting action of prolactin released from a grafted transplantable pituitary tumor (MtT/F84) on rat prostate carcinogenesis

Cancer Lett. 1990 Sep;53(2-3):151-7. doi: 10.1016/0304-3835(90)90208-f.

Abstract

The potential modifying effects of high prolactinemia on rat prostate carcinogenesis was investigated. Male F344 rats were treated at 5 times of 5-week intervals with s.c. injections of 3,2'-dimethyl-4-aminobiphenyl (DMAB), each injection following 3 weeks pretreatment with dietary ethinyl estradiol. After completion of the carcinogen administration stage, rats received multiple s.c. transplantations of a prolactin producing transplantable pituitary tumor, MtT/F84 until sacrifice at week 51. The effects of additional or single treatment with bromocriptine, a prolactin suppressing agent, were also investigated. The body, liver and kidney but prostate weights were significantly increased in the groups given MtT/F84. Although the development of prostate carcinomas was not affected by the observed hyperprolactinemia, the incidences of atypical hyperplasia of both ventral and lateral prostate were significantly enhanced. The findings thus indicate that prolactin may have promoting potential for prostate carcinogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminobiphenyl Compounds / pharmacology
  • Animals
  • Bromocriptine / pharmacology
  • Carcinogens
  • Carcinoma / drug therapy
  • Carcinoma / etiology*
  • Carcinoma / pathology
  • Cocarcinogenesis
  • Male
  • Neoplasm Metastasis
  • Neoplasm Transplantation
  • Organ Size
  • Pituitary Neoplasms / physiopathology
  • Precancerous Conditions / pathology
  • Prolactin / blood*
  • Prostate / pathology
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / etiology*
  • Prostatic Neoplasms / pathology
  • Rats
  • Rats, Inbred F344
  • Seminal Vesicles / pathology

Substances

  • Aminobiphenyl Compounds
  • Carcinogens
  • 2',3-dimethyl-4-aminobiphenyl
  • Bromocriptine
  • Prolactin